Buy Alembic Pharma; target of Rs 82: Angel Broking

“Alembic Pharma (Alembic) reported a strong performance for 3QFY2012. The company’s growth was driven by the exports and domestic formulation business (which performed better than others), as restructuring of the business has now started showing results. Alembic reported robust sales growth and improvement in OPM during the quarter. At the CMP, the stock is trading at attractive valuations. Hence, we maintain our Buy view on the stock.”

“Alembic reported strong revenue growth of 15.5% yoy to Rs381cr, although the domestic formulation business grew by just 7.9%. However, the main growth driver was the exports segment, which grew by 50.4% yoy, driven by the API and formulations business. OPM for the quarter came in at 17.8% (15.3% in 2QFY2012). During the quarter, the company recorded net profit of Rs44cr, primarily driven by revenue growth and expansion in OPM.”

“Alembic’s growth and profitability profile has improved post the restructuring carried out by management. Over FY2011-13, we expect the company to post a CAGR of 15.4% and 34.8% in its sales and net profit, respectively. At the CMP, the stock is trading at attractive valuations. Hence, we maintain our Buy recommendation on the stock with a target price of Rs82,” says Angel Broking research report.

Shares held by Insurance Companies

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.